LTR Pharma（LTP）株式概要臨床段階の製薬会社であるLTRファーマ社は、オーストラリアで勃起不全（ED）治療用の経鼻スプレーの研究開発に従事している。 詳細LTP ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間41.6%減少しました。 収益が 100 万ドル未満 ( A$1M )Australian市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( A$107M )すべてのリスクチェックを見るLTP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.564.2k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-9m1m2016201920222025202620282031Revenue AU$1.1mEarnings AU$166.6kAdvancedSet Fair ValueView all narrativesLTR Pharma Limited 競合他社Island PharmaceuticalsSymbol: ASX:ILAMarket cap: AU$105.1mNyradaSymbol: ASX:NYRMarket cap: AU$113.9mArovella TherapeuticsSymbol: ASX:ALAMarket cap: AU$85.8mVita Life SciencesSymbol: ASX:VLSMarket cap: AU$136.0m価格と性能株価の高値、安値、推移の概要LTR Pharma過去の株価現在の株価AU$0.5652週高値AU$0.8152週安値AU$0.27ベータ2.361ヶ月の変化45.45%3ヶ月変化45.45%1年変化96.49%3年間の変化n/a5年間の変化n/aIPOからの変化47.37%最新ニュースNew Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m (AU$1.1m revenue, or US$793k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$77.3m market cap, or US$54.1m).分析記事 • May 01We Think LTR Pharma (ASX:LTP) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Mar 03First half 2026 earnings released: AU$0.032 loss per share (vs AU$0.016 loss in 1H 2025)First half 2026 results: AU$0.032 loss per share (further deteriorated from AU$0.016 loss in 1H 2025). Net loss: AU$5.76m (loss widened 140% from 1H 2025).New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 42% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.2m). Market cap is less than US$100m (AU$81.8m market cap, or US$58.2m).分析記事 • Oct 18We're Not Worried About LTR Pharma's (ASX:LTP) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Sep 23LTR Pharma Limited, Annual General Meeting, Oct 24, 2025LTR Pharma Limited, Annual General Meeting, Oct 24, 2025. Location: at the offices of k&l gates, 16/66 eagle street, qld 4000., brisbane Australia最新情報をもっと見るRecent updatesNew Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m (AU$1.1m revenue, or US$793k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$77.3m market cap, or US$54.1m).分析記事 • May 01We Think LTR Pharma (ASX:LTP) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Mar 03First half 2026 earnings released: AU$0.032 loss per share (vs AU$0.016 loss in 1H 2025)First half 2026 results: AU$0.032 loss per share (further deteriorated from AU$0.016 loss in 1H 2025). Net loss: AU$5.76m (loss widened 140% from 1H 2025).New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 42% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.2m). Market cap is less than US$100m (AU$81.8m market cap, or US$58.2m).分析記事 • Oct 18We're Not Worried About LTR Pharma's (ASX:LTP) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Sep 23LTR Pharma Limited, Annual General Meeting, Oct 24, 2025LTR Pharma Limited, Annual General Meeting, Oct 24, 2025. Location: at the offices of k&l gates, 16/66 eagle street, qld 4000., brisbane AustraliaReported Earnings • Aug 31Full year 2025 earnings released: AU$3.34 loss per share (vs AU$0.05 loss in FY 2024)Full year 2025 results: AU$3.34 loss per share. Net loss: AU$5.59m (loss narrowed 20% from FY 2024).お知らせ • Aug 18LTR Pharma Limited Appoints Andrew Y. Sun to Its Scientific Advisory BoardLTR Pharma Limited announced the appointment of Dr Andrew Y. Sun, M.D., a fellowship-trained urologist and nationally recognized expert in male sexual and reproductive medicine, to its Scientific Advisory Board. Based in Texas, Dr Sun brings extensive experience in prescribing PDE5 treatment protocols and will advise on integrating LTR's intranasal therapies ROXUS® and SPONTAN® into treatment pathways for erectile dysfunction, particularly for patients experiencing side effects with existing oral medications. Dr Sun is Director of Men's Health at Urology Partners of North Texas, one of the state's largest men's health clinics. He trained at Harvard Medical School, completed a residency at the Cleveland Clinic Glickman Urological and Kidney Institute, and undertook fellowship training in Male Reproductive Medicine and Surgery at UCLA. His clinical experience spans erectile dysfunction, ejaculatory dysfunction, male infertility, hormone management, and Peyronie's disease. Dr Sun is an active contributor to US national clinical guidelines and a frequent speaker at leading urology conferences. He is an active member of the American Urological Association, the American Society for Reproductive Medicine, and the International Society for Sexual Medicine. Dr Sun contributes to clinical guidelines for the Sexual Medicine Society of North America and leads national training programs in erectile restoration with Boston Scientific. As a thought leader in men's sexual health, Dr Sun is a frequent presenter at international scientific meetings and has authored multiple peer-reviewed journal articles. His expertise is widely recognized through regular appearances on prominent podcasts, including BackTable Urology, Bionic Health, and Urology Times' "Pearls & Perspectives", where he shares insights on testosterone therapy, men's health program development, and sexual dysfunction management. He has been interviewed at major conferences, including the American Urological Association annual meeting, reflecting his influential position within the urology community.分析記事 • Jul 01We're Not Very Worried About LTR Pharma's (ASX:LTP) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • Apr 01LTR Pharma Limited Announces Change of Company Secretary, Effective 1 April 2025LTR Pharma Limited advised that in accordance with ASX Listing Rule 3.16.1, that Mr. David Hwang and Ms. Elizabeth Spooner of Confidant Partners have been appointed as Joint Company Secretaries, effective immediately. For the purposes of ASX Listing Rule 12.6, Mr. David Hwang and Ms. Elizabeth Spooner will be the persons responsible for communications with ASX in relation to Listing Rule matters. Ms. Shelby Coleman will step down as Company Secretary, effective immediately.New Risk • Mar 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 58% per year over the past 5 years. Revenue is less than US$1m (AU$500k revenue, or US$312k). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (30% increase in shares outstanding). Market cap is less than US$100m (AU$83.2m market cap, or US$52.0m).分析記事 • Mar 18We're Not Very Worried About LTR Pharma's (ASX:LTP) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Jan 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$49k revenue, or US$31k). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (30% increase in shares outstanding). Market cap is less than US$100m (AU$155.6m market cap, or US$97.5m).お知らせ • Dec 11LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 25 million.LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 25 million. Security Name: Ordianry Shares Security Type: Common Stock Securities Offered: 27,173,913 Price\Range: AUD 0.92 Discount Per Security: AUD 0.0552 Transaction Features: Subsequent Direct ListingNew Risk • Dec 10New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$150.7m (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$49k revenue, or US$31k). Minor Risk Market cap is less than US$100m (AU$150.7m market cap, or US$96.4m).Board Change • Oct 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Maja McGuire was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 26LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million.LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,383,562 Price\Range: AUD 0.73 Discount Per Security: AUD 0.0438 Transaction Features: Subsequent Direct ListingNew Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$69.7m market cap, or US$46.5m).お知らせ • Dec 18LTR Pharma Limited Receives Approval from the Bellberry Human Research Ethics Committee for Bioequivalence Clinical TrialLTR Pharma Limited shared positive results from a clinical trial in a presentation at The 24th World Meeting on Sexual Medicine (WMSM) in Dubai on 16 December 2023. Associate Professor Eric Chung, a certified Fellow of the Royal Australasian College of Surgeons (RACS) and the Urological Society of Australia and New Zealand (USANZ), presented the data to a meeting of his peers in sexual health. The core objective of the study was to assess the bioavailability of SPONTAN (SDS-089 nasal Vardenafil solution) in human plasma levels (using liquid chromatography tandem mass spectrometry analysis). The study showed that SPONTAN delivered a high plasma concentration level of Vardenafil drug, based on pharmacokinetic LC/MS data analysis with robust accuracy and precision. LTR Pharma is planning to expedite its FDA 505(b)(2) regulatory process for SPONTAN. The Company has received approval from the Bellberry Human Research Ethics Committee ("HREC") for a bioequivalence clinical trial comparing SPONTAN with the FDA approved ED drug Levitra. The trial will compare the pharmacokinetics, safety, and tolerability of Vardenafil following administration of SPONTAN and Levitra® tablets in healthy male adults. Patient recruitment is expected early next year, with trial sites to open in Sydney, Australia in First Quarter CY24. Introduction: The nasal drug delivery system offers many advantages when compared with oral administration, such as a faster onset of action, easily accessible, less drug degradation, and a high rate of absorption. The SDS-089 nasal Vardenafil (VDF) solution is a unique drug formulation designed to be delivered as a spray formulation. Objective: To assess the bioavailability of SDS-089 nasal Vardenafil solution in human plasma levels using Liquid Chromatography Tandem Mass Spectrometry analysis. Methods: The SDS-089 Vardenafil HCl formulation was prepared with the active pharmaceutical ingredient to the United States Pharmacopeia (USP) standard (batch 1704002361). The SDS-089 nasal spray solution was filtered (0.22 m filter) and fitted with a nasal spray device to deliver 100 L per spray which is equivalent to 2 mg Vardenafil HCl alcoholic solution per spray. This study received approval from the Institutional Review Board and Biosafety Committee (FB18/IRB/099). Blood samples from participants were collected at time 0 (pre-dose) and across different time intervals up to 10 hours and analyzed using Liquid Chromatography Tandem Mass Spectrometry (LC/MS) to quantify the level of Vardenafil and the internal standard. This protocol allows for the preparation and analysis of human samples, quality controls (QC), standard curve preparation, and instrumental analysis. During the validation experiments, each calibration standard and QC sample was prepared by spiking a specified amount of Vardenafil in human plasma with oral Vardenafil drug served as the internal standard for comparison. The concentration of analytes in each standard was quantified using LC/MS and detected using multiple reaction monitoring for each of the respective analytes. The lower limit of quantitation (LLOQ) was defined as the lowest concentration that could be quantified with accuracy and precision within 20%, as calculated from chromatograms for the independent samples. Intra- and inter-run accuracy and precision were calculated for the three QC samples, and independent triplicate measurements with best-fit lines were selectedusing a linear regression model with a 1/x2 weighting factor in the calibration curves. Results: The SDS-089 nasal Vardenafil solution showed excellent accuracy (mean 100, Standard Deviation, SD 4.1, % Relative Standard Deviation, RSD of 4%) and good precision (mean 50.1, SD 2.1, %RSD of 4%) on high (50ng/ml) QC assay tests. Similarly, the stability of QC on high (50ng/ml) plasma assay tests showed excellent accuracy (mean 100.8, SD 3.7, %RSD of 4%) and good precision (mean 50.4, SD 1.8, %RSD of 4%) on high (50ng/ml). Comparison between pharmacokinetic parameters of Vardenafil SDS-089 nasal spray (4mg) and oral tablet (10mg) showed T1/2 (2.52±0.99 vs 2.46±0.73 hour), Tmax (0.17±0.54 vs 0.97±0.35 hour), Cmax (time concentrations) (9.21±4.11 vs 11.24±7.83 ng/mL) and AUC0-inf (area under the curve from zero to infinity) (21.03±12.54 vs 37.25±41.51 ng/mL*h) . Conclusions: SDS-089 nasal formulation appeared to deliver a high plasma concentration level of Vardenafil drug based on pharmacokinetic LC/MS data analysis with robust accuracy and precision.株主還元LTPAU PharmaceuticalsAU 市場7D7.7%-1.6%0.6%1Y96.5%-15.4%3.3%株主還元を見る業界別リターン: LTP過去 1 年間で-15.4 % の収益を上げたAustralian Pharmaceuticals業界を上回りました。リターン対市場: LTP過去 1 年間で3.3 % の収益を上げたAustralian市場を上回りました。価格変動Is LTP's price volatile compared to industry and market?LTP volatilityLTP Average Weekly Movement15.6%Pharmaceuticals Industry Average Movement9.4%Market Average Movement10.2%10% most volatile stocks in AU Market17.4%10% least volatile stocks in AU Market4.0%安定した株価: LTPの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: LTPの weekly volatility ( 16% ) は過去 1 年間安定していますが、依然としてAustralianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2020n/an/awww.ltrpharma.comLTR Pharma Limitedは臨床段階にある製薬会社で、オーストラリアで勃起不全（ED）治療用の経鼻スプレーの研究開発に従事している。同社の主要製品候補は、経鼻送達技術であるSPONTAN、経口PDE5阻害剤、ED治療薬バルデナフィルHCLである。同社は2020年に法人化され、オーストラリアのブリスベンに本社を置いている。もっと見るLTR Pharma Limited 基礎のまとめLTR Pharma の収益と売上を時価総額と比較するとどうか。LTP 基礎統計学時価総額AU$107.25m収益（TTM）-AU$8.95m売上高(TTM)AU$1.13m90.0xP/Sレシオ-11.4xPER（株価収益率LTP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計LTP 損益計算書（TTM）収益AU$1.13m売上原価AU$4.53m売上総利益-AU$3.40mその他の費用AU$5.55m収益-AU$8.95m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.049グロス・マージン-300.25%純利益率-791.01%有利子負債／自己資本比率0%LTP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/22 02:00終値2026/06/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LTR Pharma Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m (AU$1.1m revenue, or US$793k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$77.3m market cap, or US$54.1m).
分析記事 • May 01We Think LTR Pharma (ASX:LTP) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Mar 03First half 2026 earnings released: AU$0.032 loss per share (vs AU$0.016 loss in 1H 2025)First half 2026 results: AU$0.032 loss per share (further deteriorated from AU$0.016 loss in 1H 2025). Net loss: AU$5.76m (loss widened 140% from 1H 2025).
New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 42% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.2m). Market cap is less than US$100m (AU$81.8m market cap, or US$58.2m).
分析記事 • Oct 18We're Not Worried About LTR Pharma's (ASX:LTP) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Sep 23LTR Pharma Limited, Annual General Meeting, Oct 24, 2025LTR Pharma Limited, Annual General Meeting, Oct 24, 2025. Location: at the offices of k&l gates, 16/66 eagle street, qld 4000., brisbane Australia
New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m (AU$1.1m revenue, or US$793k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$77.3m market cap, or US$54.1m).
分析記事 • May 01We Think LTR Pharma (ASX:LTP) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Mar 03First half 2026 earnings released: AU$0.032 loss per share (vs AU$0.016 loss in 1H 2025)First half 2026 results: AU$0.032 loss per share (further deteriorated from AU$0.016 loss in 1H 2025). Net loss: AU$5.76m (loss widened 140% from 1H 2025).
New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 42% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.2m). Market cap is less than US$100m (AU$81.8m market cap, or US$58.2m).
分析記事 • Oct 18We're Not Worried About LTR Pharma's (ASX:LTP) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Sep 23LTR Pharma Limited, Annual General Meeting, Oct 24, 2025LTR Pharma Limited, Annual General Meeting, Oct 24, 2025. Location: at the offices of k&l gates, 16/66 eagle street, qld 4000., brisbane Australia
Reported Earnings • Aug 31Full year 2025 earnings released: AU$3.34 loss per share (vs AU$0.05 loss in FY 2024)Full year 2025 results: AU$3.34 loss per share. Net loss: AU$5.59m (loss narrowed 20% from FY 2024).
お知らせ • Aug 18LTR Pharma Limited Appoints Andrew Y. Sun to Its Scientific Advisory BoardLTR Pharma Limited announced the appointment of Dr Andrew Y. Sun, M.D., a fellowship-trained urologist and nationally recognized expert in male sexual and reproductive medicine, to its Scientific Advisory Board. Based in Texas, Dr Sun brings extensive experience in prescribing PDE5 treatment protocols and will advise on integrating LTR's intranasal therapies ROXUS® and SPONTAN® into treatment pathways for erectile dysfunction, particularly for patients experiencing side effects with existing oral medications. Dr Sun is Director of Men's Health at Urology Partners of North Texas, one of the state's largest men's health clinics. He trained at Harvard Medical School, completed a residency at the Cleveland Clinic Glickman Urological and Kidney Institute, and undertook fellowship training in Male Reproductive Medicine and Surgery at UCLA. His clinical experience spans erectile dysfunction, ejaculatory dysfunction, male infertility, hormone management, and Peyronie's disease. Dr Sun is an active contributor to US national clinical guidelines and a frequent speaker at leading urology conferences. He is an active member of the American Urological Association, the American Society for Reproductive Medicine, and the International Society for Sexual Medicine. Dr Sun contributes to clinical guidelines for the Sexual Medicine Society of North America and leads national training programs in erectile restoration with Boston Scientific. As a thought leader in men's sexual health, Dr Sun is a frequent presenter at international scientific meetings and has authored multiple peer-reviewed journal articles. His expertise is widely recognized through regular appearances on prominent podcasts, including BackTable Urology, Bionic Health, and Urology Times' "Pearls & Perspectives", where he shares insights on testosterone therapy, men's health program development, and sexual dysfunction management. He has been interviewed at major conferences, including the American Urological Association annual meeting, reflecting his influential position within the urology community.
分析記事 • Jul 01We're Not Very Worried About LTR Pharma's (ASX:LTP) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • Apr 01LTR Pharma Limited Announces Change of Company Secretary, Effective 1 April 2025LTR Pharma Limited advised that in accordance with ASX Listing Rule 3.16.1, that Mr. David Hwang and Ms. Elizabeth Spooner of Confidant Partners have been appointed as Joint Company Secretaries, effective immediately. For the purposes of ASX Listing Rule 12.6, Mr. David Hwang and Ms. Elizabeth Spooner will be the persons responsible for communications with ASX in relation to Listing Rule matters. Ms. Shelby Coleman will step down as Company Secretary, effective immediately.
New Risk • Mar 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 58% per year over the past 5 years. Revenue is less than US$1m (AU$500k revenue, or US$312k). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (30% increase in shares outstanding). Market cap is less than US$100m (AU$83.2m market cap, or US$52.0m).
分析記事 • Mar 18We're Not Very Worried About LTR Pharma's (ASX:LTP) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Jan 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$49k revenue, or US$31k). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (30% increase in shares outstanding). Market cap is less than US$100m (AU$155.6m market cap, or US$97.5m).
お知らせ • Dec 11LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 25 million.LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 25 million. Security Name: Ordianry Shares Security Type: Common Stock Securities Offered: 27,173,913 Price\Range: AUD 0.92 Discount Per Security: AUD 0.0552 Transaction Features: Subsequent Direct Listing
New Risk • Dec 10New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$150.7m (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$49k revenue, or US$31k). Minor Risk Market cap is less than US$100m (AU$150.7m market cap, or US$96.4m).
Board Change • Oct 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Maja McGuire was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 26LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million.LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,383,562 Price\Range: AUD 0.73 Discount Per Security: AUD 0.0438 Transaction Features: Subsequent Direct Listing
New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$69.7m market cap, or US$46.5m).
お知らせ • Dec 18LTR Pharma Limited Receives Approval from the Bellberry Human Research Ethics Committee for Bioequivalence Clinical TrialLTR Pharma Limited shared positive results from a clinical trial in a presentation at The 24th World Meeting on Sexual Medicine (WMSM) in Dubai on 16 December 2023. Associate Professor Eric Chung, a certified Fellow of the Royal Australasian College of Surgeons (RACS) and the Urological Society of Australia and New Zealand (USANZ), presented the data to a meeting of his peers in sexual health. The core objective of the study was to assess the bioavailability of SPONTAN (SDS-089 nasal Vardenafil solution) in human plasma levels (using liquid chromatography tandem mass spectrometry analysis). The study showed that SPONTAN delivered a high plasma concentration level of Vardenafil drug, based on pharmacokinetic LC/MS data analysis with robust accuracy and precision. LTR Pharma is planning to expedite its FDA 505(b)(2) regulatory process for SPONTAN. The Company has received approval from the Bellberry Human Research Ethics Committee ("HREC") for a bioequivalence clinical trial comparing SPONTAN with the FDA approved ED drug Levitra. The trial will compare the pharmacokinetics, safety, and tolerability of Vardenafil following administration of SPONTAN and Levitra® tablets in healthy male adults. Patient recruitment is expected early next year, with trial sites to open in Sydney, Australia in First Quarter CY24. Introduction: The nasal drug delivery system offers many advantages when compared with oral administration, such as a faster onset of action, easily accessible, less drug degradation, and a high rate of absorption. The SDS-089 nasal Vardenafil (VDF) solution is a unique drug formulation designed to be delivered as a spray formulation. Objective: To assess the bioavailability of SDS-089 nasal Vardenafil solution in human plasma levels using Liquid Chromatography Tandem Mass Spectrometry analysis. Methods: The SDS-089 Vardenafil HCl formulation was prepared with the active pharmaceutical ingredient to the United States Pharmacopeia (USP) standard (batch 1704002361). The SDS-089 nasal spray solution was filtered (0.22 m filter) and fitted with a nasal spray device to deliver 100 L per spray which is equivalent to 2 mg Vardenafil HCl alcoholic solution per spray. This study received approval from the Institutional Review Board and Biosafety Committee (FB18/IRB/099). Blood samples from participants were collected at time 0 (pre-dose) and across different time intervals up to 10 hours and analyzed using Liquid Chromatography Tandem Mass Spectrometry (LC/MS) to quantify the level of Vardenafil and the internal standard. This protocol allows for the preparation and analysis of human samples, quality controls (QC), standard curve preparation, and instrumental analysis. During the validation experiments, each calibration standard and QC sample was prepared by spiking a specified amount of Vardenafil in human plasma with oral Vardenafil drug served as the internal standard for comparison. The concentration of analytes in each standard was quantified using LC/MS and detected using multiple reaction monitoring for each of the respective analytes. The lower limit of quantitation (LLOQ) was defined as the lowest concentration that could be quantified with accuracy and precision within 20%, as calculated from chromatograms for the independent samples. Intra- and inter-run accuracy and precision were calculated for the three QC samples, and independent triplicate measurements with best-fit lines were selectedusing a linear regression model with a 1/x2 weighting factor in the calibration curves. Results: The SDS-089 nasal Vardenafil solution showed excellent accuracy (mean 100, Standard Deviation, SD 4.1, % Relative Standard Deviation, RSD of 4%) and good precision (mean 50.1, SD 2.1, %RSD of 4%) on high (50ng/ml) QC assay tests. Similarly, the stability of QC on high (50ng/ml) plasma assay tests showed excellent accuracy (mean 100.8, SD 3.7, %RSD of 4%) and good precision (mean 50.4, SD 1.8, %RSD of 4%) on high (50ng/ml). Comparison between pharmacokinetic parameters of Vardenafil SDS-089 nasal spray (4mg) and oral tablet (10mg) showed T1/2 (2.52±0.99 vs 2.46±0.73 hour), Tmax (0.17±0.54 vs 0.97±0.35 hour), Cmax (time concentrations) (9.21±4.11 vs 11.24±7.83 ng/mL) and AUC0-inf (area under the curve from zero to infinity) (21.03±12.54 vs 37.25±41.51 ng/mL*h) . Conclusions: SDS-089 nasal formulation appeared to deliver a high plasma concentration level of Vardenafil drug based on pharmacokinetic LC/MS data analysis with robust accuracy and precision.
